Hudson Bay Capital Management
ANAB icon

Hudson Bay Capital Management’s AnaptysBio ANAB Stock Holding History

Hudson Bay Capital Management’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-20,000
Closed -$700K – 427
2019
Q3 		$700K Buy
+20,000
New +$952K 0.02% 333

Other funds holding ANAB

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Hudson Bay Capital Management's ANAB Position: Q3 2024 in Review

Hudson Bay Capital Management sold out of AnaptysBio (ANAB) in Q3 2024, closing a stake of 55,000 shares — an estimated $1.38M sold.

Hudson Bay Capital Management first reported a position in ANAB in Q2 2018 and held it in 12 quarters. The position peaked at $4.66M in Q2 2019. 160 funds tracked by Wall St. Rank hold ANAB as of Q3 2024.

  • Hudson Bay Capital Management reported no remaining AnaptysBio position as of Q3 2024 after selling out during the quarter.
  • Hudson Bay Capital Management sold 55,000 AnaptysBio shares in Q3 2024, an estimated $1.38M.
  • Hudson Bay Capital Management first reported a position in AnaptysBio in Q2 2018 and held it in 12 quarters.
  • Hudson Bay Capital Management's AnaptysBio position peaked at $4.66M in Q2 2019.
  • 160 funds tracked by Wall St. Rank held AnaptysBio as of Q3 2024.

Based on Hudson Bay Capital Management's 13F filing for Q3 2024, filed 13 Nov 2024.